Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies
Authors' conclusion
At 12/20 years after treatment started, the majority of RA and UA patients who had been treated to target low DAS or DAS remission were in DAS remission and had limited functional disability. Radiographic damage progression was mild although not completely suppressed.
Study context
- Population
- Patients with early RA or undifferentiated arthritis treated-to-target in the BeSt and IMPROVED trials, invited for follow-up 2019–22
- Participants
- 153 vs 282
- Comparison
- ex-BeSt vs ex-IMPROVED
- ex-BeStn = 153
- ex-IMPROVEDn = 282
Methodological detailstreat-to-target
- Treat-to-target
Primary result
As reported in the abstract
Long-term disease outcomes · median 12 and 20 years since study start
| Group | Value | SHS progression since end BeSt, median (IQR) | HAQ, mean ± SD | HAQ change since end BeSt | SHS progression since end IMPROVED, median (IQR) | HAQ change since end IMPROVED |
|---|---|---|---|---|---|---|
| ex-BeSt | median 14.0 (IQR 6.0–32.5) SHS | 6.0 (2.0-12.5) | 0.8 ± 0.6 | 0.3 ± 0.5 | ||
| ex-IMPROVED | median 8 (IQR 3–16) SHS | 0.6 ± 0.6 | 4 (2-9) | 0.06 ± 0.5 |
Value
ex-BeStmedian 14.0 (IQR 6.0–32.5) SHS
ex-IMPROVEDmedian 8 (IQR 3–16) SHS
SHS progression since end BeSt, median (IQR)
ex-BeSt6.0 (2.0-12.5)
ex-IMPROVED— not stated in the abstract
HAQ, mean ± SD
ex-BeSt0.8 ± 0.6
ex-IMPROVED0.6 ± 0.6
HAQ change since end BeSt
ex-BeSt0.3 ± 0.5
ex-IMPROVED— not stated in the abstract
SHS progression since end IMPROVED, median (IQR)
ex-BeSt— not stated in the abstract
ex-IMPROVED4 (2-9)
HAQ change since end IMPROVED
ex-BeSt— not stated in the abstract
ex-IMPROVED0.06 ± 0.5
- Low disease activity, ex-BeSt and ex-IMPROVED combined
- 91%
- DAS remission, ex-BeSt and ex-IMPROVED combined
- 68%
Original publication
Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies. Rheumatology (Oxford). Published 1 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →